# A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Source: https://onco.cc/trials/nct06111235/  
OnCo record `nct06111235` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Cretostimogene grenadenorepvec in bladder & urothelial cancer, run by CG Oncology, Inc., active and no longer recruiting.

## Summary

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT is a phase 3 interventional study registered as NCT06111235 by CG Oncology, Inc., with 367 participants enrolled, started 2023-12-14 and due to reach its primary completion in 2026-11. Interventions recorded: Cretostimogene Grenadenorepvec.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06111235
- Phase: 3
- Setting: A Phase 3, Randomized Study of Adjuvant Cretostimogene Grenadenorepvec Versus Observation for the Treatment of Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR-NMIBC) Following Transurethral Resection of Bladder Tumor (TURBT)
- Sponsor: CG Oncology, Inc.
- Enrolled: 367

## Sources

- ClinicalTrials.gov NCT06111235: https://clinicaltrials.gov/study/NCT06111235

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Cretostimogene grenadenorepvec](https://onco.cc/drugs/cretostimogene/)

---
JSON: https://onco.cc/api/v1/entities/nct06111235.json